OphRx Overview

  • Founded
  • 2014

  • Status
  • Private

  • Latest Deal Type
  • Joint Venture

  • Latest Deal Amount
  • $1M

  • Investors
  • 4

OphRx General Information


Developer of a non-invasive drug delivery technology designed to treat diseases of the eye. The company's technology uses lyotropic liquid crystals, a non-invasive alternative to current delivery modalities, enabling healthcare providers to treat diseases at the front and the back of the eye, such as intravitreal injections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Primary Office
  • Kiryat Atidim Building 7
  • 2nd Floor
  • Tel Aviv 6158101
  • Israel
+972 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OphRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Joint Venture 01-Jan-2014 $1M Completed Pre-Clinical Trials
To view OphRx’s complete valuation and funding history, request access »

OphRx Executive Team (1)

Name Title Board Seat Contact Info
Robert David Chief Medical Officer
To view OphRx’s complete executive team members history, request access »

OphRx Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioLight Life Sciences Venture Capital Minority 000 0000 000000 0
Integra Holdings Venture Capital Minority 000 0000 000000 0
Kremer and Lieberman Groups Other Minority 000 0000 000000 0
XL-Vision Sciences Corporation Minority 000 0000 000000 0
To view OphRx’s complete investors history, request access »